Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

Separately, Oppenheimer lifted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Astria Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Trading Down 1.9 %

Shares of NASDAQ:ATXS opened at $7.41 on Thursday. The company has a 50-day moving average price of $9.12 and a 200 day moving average price of $10.57. Astria Therapeutics has a 12 month low of $7.16 and a 12 month high of $16.90. The company has a market cap of $418.18 million, a price-to-earnings ratio of -3.55 and a beta of 0.70.

Institutional Trading of Astria Therapeutics

Large investors have recently bought and sold shares of the stock. FMR LLC boosted its position in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. boosted its holdings in Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the last quarter. Vestal Point Capital LP increased its stake in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after acquiring an additional 218,518 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in shares of Astria Therapeutics in the second quarter valued at approximately $6,142,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.